Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Dyax agrees Kadmon strategic licensing agreement for DX-2400

Dyax : 21 September, 2012  (Company News)
Dyax is entering into a strategic licensing agreement with Kadmon which will see Kadmon being granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective antibody inhibitor of matrix metalloproteinase 14 (MMP-14).


MMP-14 is a key enzyme in a molecular pathway thought to play a role in tumour blood vessel formation (angiogenesis) in addition to affecting tumour growth and cell migration. Under the terms of the agreement, Dyax will receive an upfront payment, and is eligible for significant development and commercial milestone payments, in addition to tiered royalties on commercial sales up to a double-digit rate. As an exclusive licensee, Kadmon will be responsible for further development and commercialization of DX-2400, which is currently in investigational new drug (IND) application-enabling studies.



"Kadmon's management team has a proven track record of successfully developing and commercializing important, new oncology products," said Gustav Christensen, President and Chief Executive Officer of Dyax. "This strategic agreement further validates Dyax's capabilities to successfully discover novel antibody drug candidates utilizing our proprietary phage display technology and advance the resulting drug candidates into development."



"This agreement expands on our longstanding relationship with Dyax and their antibody technology platform," said Samuel Waksal, PhD. Chairman and Chief Executive Officer of Kadmon. "We believe MMP-14 is an important piece of the puzzle for overcoming cancer's growth, proliferation and resistance mechanisms. In particular, its role in tumours and ocular disease neovascularization represents a unique target opportunity that may be complementary to other antiangiogenic therapies on the market and in development. We look forward to developing this candidate, and to fully understanding its synergistic potential with our oncology pipeline products."



Targeting MMP-14 has therapeutic potential in multiple oncology indications where human tumour tissue sample analysis has confirmed high levels of active MMP-14. In published work, Dyax has previously demonstrated DX-2400 mediated inhibition of primary tumour growth, metastasis and angiogenesis in preclinical models of breast, melanoma and prostate cancer.



DX-2400 was discovered using Dyax's 'gold-standard' phage display technology where Dyax applied its extensive selection and screening expertise to selectively block catalytic activity of a single protease within a larger and closely related family of enzymes. This antibody is another example of the superior functional selectivity available to validate novel biologic targets using Dyax's phage display libraries.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo